Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
The EuroBiotech Journal
Volume 5 (2021): Issue 4 (October 2021)
Open Access
SCM-198 Can Regulate Autophagy Through the Bax/Bcl-2/TLR4 Pathway to Alleviate Renal Ischemia-Reperfusion Injury
Ersen Eraslan
Ersen Eraslan
,
Burak Bircan
Burak Bircan
,
Ayhan Tanyeli
Ayhan Tanyeli
,
Mustafa Can Güler
Mustafa Can Güler
,
Yasin Bayır
Yasin Bayır
and
Serdar Altun
Serdar Altun
| Oct 21, 2021
The EuroBiotech Journal
Volume 5 (2021): Issue 4 (October 2021)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research article
Published Online:
Oct 21, 2021
Page range:
161 - 169
DOI:
https://doi.org/10.2478/ebtj-2021-0025
Keywords
SCM-198
,
Renal ischemia-reperfusion
,
Renal injury
,
Inflammatory cytokines
,
Autophagy
,
Bax
,
Bcl-2
© 2021 Ersen Eraslan, Burak Bircan, Ayhan Tanyeli, Mustafa Can Güler, Yasin Bayır, Serdar Altun, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
SCM-198 chemical structure.
Figure 2
Effects of SCM-198 on kidney functions. (A) Urea and (B) Cre levels. *P<0.05 compared to the control and DMSO groups, ϕP<0.05 compared to the I/R group.
Figure 3
Effects of SCM- 198 on inflammatory cytokines. (A) TNF-α, (B) IL-1β and (C) IL- 18 levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
Figure 4
Changes in kidney damage biomarkers in the kidney I/ R model (A) NGAL, (B) KIM-1, and (C) PCX levels. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
Figure 5
(A) Control group, LC3B immunonegativity (B) DMSO group, LC3B immunonegativity (C) I/R group, moderate LC3B immunopositivity was observed in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild LC3B immunopositivity was detected in renal tubular epithelial cells (arrowhead).
Figure 6
(A) Control group, Beclin-1 immunonegativity, (B) DMSO group, Beclin-1 immunonegativity, (C) I/R group, moderate Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM -198 group, mild Beclin-1 immunopositivity in renal tubule epithelial cells (arrowhead).
Figure 7
(A) Control group, TLR4 immunonegativity, (B) DMSO group, TLR4 immunonegativity, (C) I/R group, moderate TLR4 immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild TLR4 immunopositivity in renal tubule epithelial cells (arrowhead).
Figure 8
(A) Control group, Bax immunonegativity, (B) DMSO group, Bax immunonegativity, (C) I/R group, moderate Bax immunopositivity in renal tubule epithelial cells (arrowhead), (D) SCM-198 group, mild Bax immunopositivity in renal tubule epithelial cells (arrowhead).
Figure 9
(A) Control group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (B) DMSO group, severe Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead), (C) I/R group, mild Bcl-2 immunopositivity in renal tubule epithelial cells, (D) SCM-198 group, moderate Bcl-2 immunopositivity in renal tubule epithelial cells (arrowhead).
Figure 10
IHC scoring in renal tubule cells (A) LC3B, (B) Beclin-1, (C) TLR4, (D) Bax and (E) Bcl-2. *P<0.05 compared to control and DMSO groups, ϕP<0.05 compared to I/R group.
Preview